anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators propose a randomized controlled trial (RCT) of CBT-DD, enhanced by CGM feedback. The study period will last for 6 months, with the first 3 months on CGM and consisting of a 2-week run-in period prior to randomization, in which EMA (ecological momentary assessment) data will be collected daily, followed by an 8-week CBT intervention period in which EMA data will be collected weekly surrounding CBT sessions, with a subsequent 2-week period post-intervention in which EMA data will again be collected daily. Both intervention and control groups will be doing the same EMA and CGM procedures to enable matching data for comparison. Follow-up virtual study data collection will occur at 3, 6, 9, and 12 months to assess the primary outcome of HbA1c and durability of intervention effect on diabetes distress and HbA1c. Participants in both arms will be provided a sufficient supply of CGM sensors to track their blood glucose daily, throughout the first 6 months of the study. If participants already have personal CGM, they will replace with study-supplied CGM.

We will also collect qualitative information from people with Type 1 Diabetes (T1D) ages 35-64 to solicit suggestions and inform future study decisions. We will create 2-4 focus groups to ask their impressions about our current study and explore key factors like establishing adult care and attending medical appointments, disease self-management, and adjusting to chronic disease. We will compare interview responses from participant groups who have high vs. low social needs and poor vs. good glycemic control.
The research will be conducted in six high schools, three of which are intervention schools . Schools in the district will be divided into 3 layers as 1- Anatolian High Schools, 2- Technical and Vocational High Schools, 3- Imam Hatip High Schools.
This was a prospective, observational, and single-center study conducted between July-November 2018. The study protocol was approved by the Local Ethics Committee. The study was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from the parent.

The patients were separated into four groups according to the anaesthetic agents given.Intranasal premedication was applied to all the patients, then an intravenous cannula was placed and the anaesthetic agents were administered intravenously. The Ramsay Sedation Scale (RSS) was used to evaluate the level of sedation, with a target of 5 points. The RSS is scored from 1-6 as follows: 1: the patient is worried and anxious, or restless, 2: the patient is calm and co-operative, and can be directed, 3: the patient only responds to instructions, 4: the patient responds rapidly to painful stimuli, 5: the patient demonstrates a slow response to painful stimuli, 6: the patient does not respond. When RSS 5 was reached following the first bolus dose of the drug, an additional dose was administered. When RSS 5 was obtained and hemodynamic stability was ensured, the patient was placed on the MRI table.

The patient was monitored in the recovery room for regaining consciousness for up to 30 mins after the procedure. AED was evaluated using the PAED scale by a nurse trained in the use of this scale. PAED scoring was repeated every 5 mins until the patient was discharged from the recovery room. If the PAED score was ≥10, a diagnosis of AED was made. Adverse events such as laryngospasm, desaturation (SpO2 \<95%), respiratory depression, bradycardia, allergy, hiccoughs, nystagmus, nausea, and vomiting were recorded. When a Modified Aldrete Score of \>9 was obtained, the child was observed for a further 15 mins then transferred from the recovery room.
The effect of methylprotodioscin (MPD), a steroidal saponin obtained from medicinal plants, on myocardial infarction (MI) remains elusive. In this study, HL-1 and AC16 cells were subjected to injury induced by hypoxic environment, and a mouse model of MI was established by ligating the left anterior descending. MPD significantly increased viabilities and proliferations, improved the stability of MMP, reduced ROS and inflammatory factor levels in hypoxia cardiomyocytes. Moreover, MPD significantly improved cardiac functions, increased the ventricular ejection fraction and short axis shortening rate of mice with MI, reduced the infarction area, alleviated oxidative stress and increased ATPase activities. Then, differentially expressed proteins (DEPs) were discovered and evaluated using tandem mass tag (TMT)-based proteomics and bioinformatics approaches. Compared with sham group, there were 420 DEPs in the cardiac tissue of MI group, likewise, 163 DEPs in MPD group were identified compared to MI group. By validating, the expression of COX6C was elevated in MI group and declined in MPD groups, consistent with the TMT-based proteomics results. Correspondingly, p-NF-κB expression was downregulated, while Nrf2 and SOD expressions were upregulated by MPD. Moreover, si-COX6C transfection blocked the regulatory effects of MPD on COX6C-mediated inflammation and oxidative stress in MI. Our findings indicate that MPD, a naturally occurring active ingredient, could effectively improve cardiac function. Its ability may result from regulating COX6C to reduce oxidative stress and suppress inflammation, suggesting that MPD is very attractive for the treatment of MI.
The present invention relates to a coated hypericum perforatus extract micro pill preparation and a preparation process thereof. The preparation is prepared from a micro pill containing a hypericum perforatus extract and an external film coating. The micro pill has the following component proportion by the ratio of weight parts: 180 to 240 shares of blank pill cores, 16 to 60 shares of extracts, 6 to 10 shares of talcum powder, 10 to 14 shares of microcrystalline cellulose, 0.4 to 0.8 share of vitamin C and 3 to 28 shares of PVP. The film coating has the following components and proportion by weight parts: 7.2 to 22 shares of IV acrylic resin and/or 0.3 to 2 shares of hydroxypropyl methyl cellulose, 3 to 5 shares of titanium dioxide, 1 to 3 shares of magnesium stearate, 3 to 5 shares of Tween 80 and 1.5 to 3.5 shares of PEG60001-3 or glycerol. The present invention increases the heat-resistant performance, the light-resistant performance and the oxygen-resistant performance of the preparation by selecting the auxiliary materials which are suitable for the forming of the hypericum perforatus extract micro pill, the kinds and the dosage of antioxidants, and sieving film coating materials which can be operated at low temperature and the coating process. The effective components of the film coating micro pill preparation of the obtained hypericum perforatus extract have favorable stability, and the present invention overcomes the instable problem of the usual preparations of the existing hypericum perforatus.
FIELD: cosmetics. SUBSTANCE: the suggested cosmetic preparation includes oily extract of bur marigold, oily extract of wheat germs, essential oil of bergamot, essential oil of grapefruit, essential oil of rosemary, and, also, Graphites C6, melissa C3, Salvia C3 and Symphytum C6 and foundation consisting of spermaceti, bee wax, cacao oil, emulsion wax and distilled water taken at certain quantitative ratio. Preparation is designed as a cream. The latter has got no irritating action and normalizes water-adipose metabolism of skin. EFFECT: higher efficiency. 1 tbl
A dental implant includes an insert element of a titanium-based material inserted and soldered into a blind hole in an anchoring element of a ceramic material. An outer surface of the insert element has spacer members to center the insert element in the blind hole, with a uniform circumferential gap space relative to the anchoring element. The insert element is longer than the blind hole, so that a portion of the insert element protrudes outwardly beyond an end face of the anchoring element. The blind hole is partly filled with a glass solder suspension, and the insert element is inserted into the blind hole, whereby an excess amount of the glass solder is displaced out of the gap space onto the end face of the anchoring element and the protruding portion of the insert element. A thermal soldering process secures the insert element into the anchoring element. The protruding portion of the insert element and remaining excess solder is removed to form a planar surface.
The invention discloses a parasitic illicium verum deodorizing spraying agent. The spraying agent can eliminate the sweat stink or body odor secreted during the movement process after being sprayed on the human body. The spraying agent is prepared by the following steps: washing parasitic illicium verum, cutting into sections with a length of 1 to 5 millimeters, soaking the sections in liquor with a concentration of 45 to 50 degrees for 3 to 10 days, wherein the weight ratio of the sections to the liquor is 1:0.8-1.2, filtering to obtain a soaking liquid, and then loading the liquid in a spraying bottle so as to obtain the spraying agent. The spraying agent has been applied to 2100 persons. The spraying agent can be sprayed to the armpit or parts that secret sweat. When the body feels the wet feeling, the spraying amount is enough. After 3 to 10 minutes, the spraying liquid will evaporate, the body odor diffused from the skin and body surface will be eliminated, and the human body becomes odorless and has a light fragrance. The provided spraying agent has a function o f eliminating human body odor. The spraying agent has the advantages of easily-available raw materials, simple preparation method, prominent effect, easy application, and low cost.
A qualitative researcher will undertake 25-30 semi-structured interviews with participants who have volunteered their contact details in the final section of the EUNASS Study Questionnaire. A purposive sampling approach will be taken for participant recruitment to this part of the study.
At UAB oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 92-95% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed for a 2 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets.
In a 70-day double-blind, placebo-controlled add-on trial in the Lennox-Gastaut syndrome, Felbatol® 45 mg/kg/day given QID was superior to placebo in controlling the multiple seizure types associated with this condition. Patients had at least 90 atonic and/or atypical absence seizures per month while receiving therapeutic dosages of one or two other antiepileptic drugs. Patients had a past history of using an average of eight antiepileptic drugs. The most commonly used antiepileptic drug during the baseline period was valproic acid. The frequency of all types of seizures during the baseline period was 1617 per month in the Felbatol® group and 716 per month in the placebo group. Statistically significant differences in the effect on seizure frequency favored Felbatol® over placebo for total seizures (26% reduction vs. 5% increase, P<.001), atonic seizures (44% reduction vs. 7% reduction, P=.002), and generalized tonic-clonic seizures (40% reduction vs. 12% increase, P=.017). Parent/guardian global evaluations based on impressions of quality of life with respect to alertness, verbal responsiveness, general well-being, and seizure control significantly (P<.001) favored Felbatol® over placebo.

When efficacy was analyzed by gender in four well-controlled trials of felbamate as adjunctive and monotherapy for partial-onset seizures and Lennox-Gastaut syndrome, a similar response was seen in 122 males and 142 females.
The invention provides an EPA composition comprising: from 15 wt. % to 90 wt. % eicosapentaenoic acid (EPA) and 10 wt. % to 70 wt. % polar lipids, wherein the polar lipids comprise phospholipid conjugates and glycolipid conjugates, 5 wt. % to 50 wt. % of the EPA in the composition is a glycolipid conjugate, 3 wt. % to 50 wt. % of the EPA in the composition is a phospholipid conjugate, and 0 wt. % to 10 wt. % of the EPA in the composition is a triglyceride conjugate or a diglyceride conjugate, and wherein the composition comprises less than 5 wt. % esterified EPA, does not comprise docosahexaenoic acid (DHA), and wherein the composition is suitable for human consumption. The invention also provides an EPA composition comprising the following distribution of EPA by lipid class: 3 wt. % to 50 wt. % of the EPA is a phospholipid conjugate; 5 wt. % to 50 wt. % of the EPA is a glycolipid conjugate; 0 wt. % to 10 wt. % of the EPA is a triglyceride conjugate or a diglyceride conjugate; and 15 wt. % to 85 wt. % of the EPA is in free fatty acid form, wherein the composition is suitable for human consumption. The invention also provides methods of producing an EPA composition of this invention.
BACKGROUND: Small airway remodelling is a vital characteristic of chronic obstructive pulmonary disease (COPD), which is mainly caused by epithelial barrier dysfunction and epithelial-mesenchymal transition (EMT). Recent studies have indicated that histone deacetylase 6 (HDAC6) plays an important role in the dysregulation of epithelial function. In this study, we investigated the therapeutic effects and underlying mechanisms of an inhibitor with high selectivity for HDAC6 in COPD.
METHODS: Cigarette smoke (CS) exposure was used to establish a CS-induced COPD mouse model. CAY10603 at doses of 2.5 and 10 mg/kg was injected intraperitoneally on alternate days. The protective effects of CAY10603 against CS-induced emphysema, epithelial barrier function and small airway remodeling were evaluated using hematoxylin and eosin (H&E) staining, Masson's trichrome staining, immunohistochemical staining, and western blot. The human lung bronchial epithelial cell line (HBE) was used to elucidate the underlying molecular mechanism of action of CAY10603.
RESULTS: HDAC6 levels in the lung homogenates of CS-exposed mice were higher than that those in control mice. Compared to the CS group, the mean linear intercept (MLI) of the CAY10603 treatment group decreased and the mean alveolar number (MAN)increased. Collagen deposition was reduced in groups treated with CAY10603. The expression of α-SMA was markedly upregulated in the CS group, which was reversed by CAY10603 treatment. Conversely, E-cadherin expression in the CS group was further downregulated, which was reversed by CAY10603 treatment. CAY10603 affects the tight junction protein expression of ZO-1 and occludin. ZO-1 and occludin expression were markedly downregulated in the CS group. After CAY10603treatment, the protein expression level of ZO-1 and occludin increased significantly. In HBE cells, Cigarette smoke extract (CSE) increased HDAC6 levels. CAY10603 significantly attenuated the release of TGF-β1 induced by CSE. CAY10603 significantly increased the E-cadherin levels in TGF-β1 treated HBE cells, while concurrently attenuated α-SMA expression. This effect was achieved through the suppression of Smad2 and Smad3 phosphorylation. CAY10603 also inhibited TGF-β1 induced cell migration.
CONCLUSIONS: These findings suggested that CAY10603 inhibited CS induced small airway remodelling by regulating epithelial barrier dysfunction and reversing EMT via the TGF-β1/Smad2/3 signalling pathway.
The sensor-based balance training is performed using an integrated system composed of five inertial measurement units (IMUs) and a force platform. The system analyze the data via a notebook and provide a real-time feedback for the patient in a 32 inch screen in form of exergaming.
A method can include obtaining personal data of a user and generating, based at least in part on the personal data of the user, a taste profile of the user. The taste profile can include a set of food characteristics that corresponds to one or more food preferences of the user. The method can include obtaining contextual data that corresponds to a location of the user. The method can include generating, based at least in part on the taste profile and the contextual data, a food recommendation. The food recommendation can include a predicted food preference of the user. The method can include transmitting the food recommendation to the user.
Part 1 will be the dose titration part for cyclophosphamide. Participants will receive cyclophosphamide, bortezomib, and dexamethasone for 3 cycles. In Part 2, participants will receive cyclophosphamide (dose determined in Part 1) with pre-defined dose of bortezomib and dexamethasone for 3 cycles.
Up to 12 healthy subjects will be recruited such that age and gender are similar to the CKD patients. These subjects will be recruited as negative controls for a baseline assessment of healthy physiology. These subjects will not be treated with Darbepoetin.
A manufacturing method of medication includes the following steps. Firstly, an effective dosage of an API is dissolved in a dissolved agent to form a first solution, wherein the API includes triamcinolone acetonide or YC-1 compound. Next, the first solution is filtered through a filter membrane at a room temperature to obtain a second solution. Then, a precipitating agent is added into the second solution to obtain a third solution, followed by continuously stirring the third solution to precipitate crystals. The third solution is further stirred under the room temperature, a low pressure to sequentially remove the dissolved agent and the precipitating agent. Finally, a volume of the crystals is quantified to primary package and to refill the crystals, to obtain the medication, wherein the triamcinolone acetonide and the YC-1 compound are represented by structures of formula (I) and formula (II) respectively:
PURPOSE:To obtain the titled agent for transcutaneous use, having excellent transcutaneous absorbability and prolonged activity and useful for the prevention and remedy of stenocardia, by dissolving isosorbide nitrate, polyvinyl pyrrolidone and a non-volatile liquid base in a volatile solvent at respective specific concentrations. CONSTITUTION:The objective agent is prepared by dissolving (A) 1pt.wt. of isosorbide nitrate, (B) 0.2-3pts.wt., preferably 0.3-1pt.wt. of a polyvinyl pyrrolidone (preferably having an average molecular weight of 25,000-120,000) and (C) 0.5-5pts.wt., preferably 1-3pts.wt. of a non-volatile liquid base (preferably isopropyl myristate and a polyethylene glycol having an average molecular weight of 200-600) in (D) 1-20pts.wt., preferably 3-5pts.wt. of a volatile solvent (preferably ethanol or a mixture of ethanol and acetone). The agent keeps stable concentration in blood over a long period without causing the development of side effects.
Healthy controls are matched to participants with PNES based on age (+ or - 1 year), gender, race and family income. Healthy controls and their parent come for 1 baseline laboratory visit and a follow up visit 13 weeks after the baseline visit. These visits will be identical to baseline and follow-up visits of children with PNES.
The application provides a protein inhibitor for clostridium difficile exotoxin B, a composition comprising the same and application thereof. The protein inhibitors 43829 (SEQ ID No.: 1) or H3 (SEQ ID No.: 2) of the application bind to the TcdB RBI-1 site in a broad spectrum; 5N2 (SEQ ID No.: 3) binds to the TcdB RBI-2 site in a broad spectrum. The application also provides an Fc homodimer and an Fc heterodimer fused to a protein inhibitor of the application. The protein inhibitor and the composition thereof successfully neutralize the main subtype of TcdB in vitro and in vivo, and provide an important basis for developing a new strategy for treating troublesome infectious diseases such as CDI and the like by utilizing de novo design.
<P>PROBLEM TO BE SOLVED: To provide a new method for dyeing keratin fibers, especially human keratin fibers, e.g. hair with which the discomfort related to dyeing can be limited.  <P>SOLUTION: The method is carried out as follows. A composition comprising a polyoxyethylenated sorbitan ester with ≤10 mol of ethylene oxide is applied to the scalp. A dye composition comprising at least one dye precursor is subsequently applied in order to the keratin fibers.  <P>COPYRIGHT: (C)2007,JPO&INPIT
FIELD: medicine.SUBSTANCE: invention refers to medicine and can be used to preserve viability of extremities at deep frostbites. That is ensured by applying a heat-insulating dressing on an affected limb. Dressing consists of three layers of sterile medical gauze, a sterile plastic matrix with ice cubes, a layer of alimentary aluminum foil, dense 3-centimeter layer of sterile medical cotton, a second layer of food aluminum foil. Dressing is fixed with a bandage or a mesh-tubular bandage “Relast”. Thereafter, a physiological saline with an anticoagulant warmed up in a container with a controlled heating process is introduced into a regional artery at least 3 cm from the lesion boundary. Temperature of the solution at the artery inlet is not more than 41 °C, the rate of introduction of solution is 60 drops per minute.EFFECT: invention allows maintaining viability of extremities at deep frostbites.1 cl, 1 ex
Pregnancy Prevention

The efficacy of SLYND was evaluated in Study CF111/303 (NCT02269241). This single arm multicenter, clinical trial was conducted in the U.S. The efficacy population consisted of 953 females ≤ 35 years of age with 5,547 evaluable cycles. The demographic profile for females was: mean age 26.4 years and mean BMI 28.5 kg/m 2. The racial distribution was 53.3% Caucasian; 38.5% African American; 2.2% Asian and 6% other. During these cycles, a total of 17 (1.8%) females reported pregnancy, leading to a Pearl Index (95% CI) of 4.0 (2.3, 6.4). 

One female who became pregnant during the study was breastfeeding and not included in the Pearl Index (PI) calculation. The confidence interval for the PI was calculated assuming that events of pregnancy had a Poisson distribution.

Out of the 953 females evaluated for efficacy, 332 subjects had a baseline BMI ≥ 30 (35%) and 173 females had a baseline BMI ≥ 35 (18%). Data were insufficient to analyze PI by BMI subgroups.

Effect on Bleeding Patterns

The bleeding pattern with SLYND was assessed systematically using patient diaries in Study CF111/303 in adult females.

The percentage of females experiencing scheduled bleeding or unscheduled bleeding/spotting decreased over time. Overall, the percentage of females with scheduled bleeding or spotting decreased from 81% in Cycle 1 to 26% in Cycle 13. Similarly, the overall percentage of females with unscheduled bleeding or spotting decreased from 61% in Cycle 1 to 40% in Cycle 13. The percentages of females with scheduled and unscheduled bleeding or spotting generally decreased through Cycle 10 and were maintained at a consistent level thereafter.

In Study CF111/304 conducted in Europe in post-menarchal, female, adolescents (12 through 17 years of age), bleeding data were generally consistent with those from Study CF111/303 in adult females. SLYND was associated with a decrease in the percentage of adolescent females experiencing bleeding or spotting over time. The percentage of adolescent females with scheduled bleeding or spotting decreased from 98.0% in Cycle 1 to 28.4% in Cycle 13. The percentage of adolescent females with scheduled bleeding or spotting generally decreased through Cycle 9 and was maintained at a consistent level thereafter. In contrast, the percentage of adolescent females with unscheduled bleeding or spotting was maintained at a relatively consistent level during the study (53.0% in Cycle 1 versus 52.2% in Cycle 13).

In addition to Studies CF111/303 and CF111/304, two additional studies evaluated bleeding associated with SLYND. A total of 91 females (3.5%) from these four studies discontinued SLYND due to problems with irregular bleeding or amenorrhea.